Non-alcoholic fatty liver disease

Hepatic steatosis, measured by the fatty liver index, is associated with an increased risk for mortality and cardiovascular disease among people with type 1 diabetes, research suggests.

Using an insulin pump rather than multiple daily injections may help protect people with type 1 diabetes from developing fatty liver disease, report researchers.

The SGLT1/2 inhibitor licogliflozin has reduced liver enzyme levels in people with nonalcoholic steatohepatitis in a phase 2 trial published in Nature Medicine.

Researchers report that metabolic abnormalities begin to increase at levels of liver fat commonly regarded as normal.

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

Physicians feel that nonalcoholic fatty liver disease is sidelined in type 2 diabetes management and should be formally incorporated into routine primary care pathways, say Australian researchers.

A genetic propensity for increased liver fat and lower pancreatic volume is associated with an increased risk for type 2 diabetes, say researchers.

Gastric bypass and sleeve gastrectomy both result in “almost complete clearance of liver fat” within a year after the intervention, show secondary outcomes of a randomized trial.